Skip to content

Morphine Titration with Intravenous Patient-Controlled Analgesia for Severe Cancer Pain

Morphine Titration with Intravenous Patient-Controlled Analgesia for Severe Cancer Pain

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0006890
Enrollment
38
Registered
2022-01-05
Start date
2021-08-11
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Whenever a patient complains of cancer pain, morphine injection is administered for 48 hours using a patient-controlled analgesia (PCA) device, and the pain control effect and side ef

Sponsors

Dong-A University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female over the age of 19 who provided written consent 2. If you have had cancer pain with an average NRS score of 7 or higher within the past 24 hours 3. Subjects who can accurately understand the pain intensity NRS and follow the drug use guide 4. A person who understands the purpose of this clinical trial and the procedures necessary for the clinical trial, and is able to sign and submit the informed consent form including the requirements and regulations listed in the consent form and this clinical trial protocol

Exclusion criteria

Exclusion criteria: 1. If there is a history of side effects such as decreased breathing with opioid analgesics 2. If you are taking a morphine equivalent daily dose (MEDD) of 300 mg/day or more 3. If the analgesic effect was not shown by previous administration or administration of morphine 4. Subjects with cognitive impairment or serious mental illness that will interfere with the progress of the study 5. Subjects who are pregnant, lactating, and planning to become pregnant within 1 month of participation in the study (including men) 6. Creatinine > 2 x upper limit of normal 7. Patients with severe respiratory depression ? Patients with acute and severe asthma and hypercapnia ? Patients with severe chronic obstructive airway disease ? Patients with severe chronic obstructive pulmonary disease and pulmonary heart disease ? If it is included in the following criteria in the lung function test 1. FEV1 / FVC 3.0 x ULN ? Total bilirubin >1.5 x ULN 10. When the Investigator determines that other measures of pain control may be affected.

Design outcomes

Primary

MeasureTime frame
Mean pain numeric rating scale (NRS) 1 hour after initiation of PCA

Secondary

MeasureTime frame
Rate of pain NRS =3 after 1 hour;Mean pain NRS after 2 hours, 4 hours, 24 hours, and 48 hours;Number of breakthrough pains in 24 hours;Quality of life survey through brief pain inventory;Total opioid consumption dosage used for titration(24, 48hrs);adverse events;Patient Global Impression of Change (PGI-C) evaluated by subjects

Countries

Korea, Republic of

Contacts

Public ContactSeok Jae Huh

Dong-A University Hospital

doctorhsj@dau.ac.kr+82-51-240-2576

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026